90% of HER2 positive breast cancer patients miss treating the good opportunity

90% of HER2 positive breast cancer patients miss treating the good opportunity
Zhang Zhyuan's breast cancer is kind of disease of cancer of women of our country with highest morbidity at present, have already threatened women's life and health seriously. In the breast cancer patient, 25%~30% people are positive HER2. It is reported, breast cancer of this kind recurs, the shifting rate is high, the death risk is relatively high too. What makes them unable to hold one's own life? Treat the difficult one, what kind of social concern is revealed? Recently, we walk close to HER2 positive breast cancer patient, visit these special patients Investigate: In breast cancer" She " The most fierce HER2 is positive to mean " The excessive expression of the people epidermis growth factor receptor 2 " ,Or: HER2 has already been excessively activated, excessively transmits signals, stimulate crazy hyperplasia of the cancer cell, so the malignant intensity of tumour cell of HER2 positive breast cancer patient is higher, develop faster, recur easily and distant place shift, and curative effect of taking fruit bad, prognosis in the future bad. Military the affiliated hospital of academy of medical sciences ' 307 hospitals) The river pool of oncology department of mammary gland the professor flies and introduces, because of the questions of idea and idea, most HER2 positive patients have not accepted the systematized treatment. Only HER2 positive monitoring is popularized, the patient can receive overall diagnosis. The medical circle has already reached common understanding at present: To treat it is HER2 that pass the intersection of breast cancer and a effective treatment means of expressing etc. biological target. HER2 positive breast cancer uses one - year long pertinence to treat in early days, can make the recuring rate of early HER2 positive breast cancer drop by 52%, the death risk drops by about 1/3; And to HER2 positive breast cancer patient in later period, pertinence treatment reduce death risk too apparent to improve the quality of surviving while. So, measure as soon as possible and adopt and insist the pertinence treatment has great meanings. Perplex: Disease and economic pressure hinder it is reported doubly, in the breast cancer patient of our country every year 180,000ing, 1/3 are HER2 positive breast cancer patient. Compared with other breast cancer patients, the breast cancer patient of this kind is relatively short in average life cycle, recur and the shifting rate is relatively high. However, the ones that know to disease are fuzzy and treats the double puzzlement of the expenses and let the way of the recovery of this part of patients be more bumpy. A latest investigation result reveals, the therapeutic current situation of HER2 positive breast cancer patient of our country allows of no optimist, because doctors and patients do not as fully realize the harmfulness of HER2 positive breast cancer and adopt the necessity of pertinence treatment, the breast cancer patient accepted HER2 detection to only have early later period breast cancer patient and 59.9% of 44.5%. Even in the the patient, some people go on only too immune preliminary detection to organize chemistry find that there are positive signs, can not further examine again and confirm in time. In American-European countries, all breast cancer patients can make HER2 to measure after making a definite diagnosis of. China medicine institute tumour hospital Professor Xu BingHe says: "To the intersection of HER2 and positive early positive breast cancer, use 1 - year long target to can enable the patient's recurring risk lower to treat by half on the conventionally therapeutic basis, the death risk is reduced by 1/3. This means that compared with regular treatment, if can adopt pertinence to resist HER2 treatment early, can save the life of more patients. " In addition, the economic factor is HER2 positive breast cancer patient's another great resistance. Though the policy in the field of medical insurance of treatment of cancer of the country is becoming more and more ripe, complete at present, but because the therapeutic medicine of this kind of patient is not still within the range of national medical insurance, a lot of patients have given up the pertinence treatment. Pay close attention to: Research and develop and break through or urge the breast cancer medicine to enter the medical insurance at present, there is certain improvement at the medical treatment level of HER2 positive breast cancer of our country. Multiple large-scale clinical experiments all reveal, HER2 passes the expressing early breast cancer patient and uses one - year long pertinence to treat, the risk of recuring of patient's tumour is reduced by 52%, the death risk is reduced by 33%, the average treatment in 4 years observes the result to reveal, nearly 90% of the women patients who accept pertinence treatment still survive. That is to say, suppose a HER2 positive breast cancer patient will recur in three years, has employed the pertinence treatment, after her recurring time will postpone even 10 years by 6; It will cause the brain to shift that suppose her, recur, the liver is shifted, the bone to shift, then she can reduce the death risks of 1/3 greatly through preventing the migration of these cancer cells too now. Such apparent advantage make the intersection of HER2 and positive the intersection of breast cancer and research field excitement, let more patients see that hope too. But because the target is to higherrer reason of the treatment medicine expenses, the target is still at the starting stage to the application treating at HER2 positive breast cancer. What merits attention is human resources and social security department announce the new medical insurance catalogue will it be November 2009, set up the medicine medical insurance negotiation access mechanism of the high price at the same time. Hertzs of the intersection of match and spit of fland, too in the intersection of first run and the intersection of medical insurance and row of negotiation, expected to enter medical insurance, wipe out catalogue through negotiation, lighten this part of patients' economic pressure conscientiously. What Professor Liao Ning of the People's Hospital of Guangdong Province dominated " HER-2 the cancer composition of normal position accompanies the independent prediction factor soaked for mammary gland conduit normal position cancer of the main fact " Research results,and last song pearl form researches against new auxiliary healing solutions proper, have confirmed the proper pearl form of song and resisted and treated validity and pertinence of the field at breast cancer effectively, this will promote it to enter process of catalogue of submitting an expense account through medical insurance negotiation. Measure: Launch the people and help each other, call upon the government to participate in In order to no longer let HER2 positive breast cancer patient fall into and treat the predicament, in Beijing, Shanghai, Shenzhen and other places, many cancer charity organizations, associations, clubs rise quietly, such as HER2 positive breast cancer patient's educational demonstration centre, taking good care of the club,etc., help HER2 positive patient to lengthen the life through many ways, improve life quality. Though the intersection of various circles of society and love gather, help quite one patient, lack major support of strength, the breast cancer patient survives the state has not obtained the substantive change. At present, HER2 positive breast cancer patient of our country adopts the rate of pertinence treatment to be fewer than 10%, that is to say there are 9 in 10 patients helplessly fault is treating the good opportunity. In American-European countries, pass the standard medicine to express breast cancer treatment as HER2 in one hertz of spit of fland of match, been ranking the medical insurance catalogue all the time. In our country, with the quickening of social economic development and medical process of reform in recent years, a lot of cancer standard therapeutic medicines are all included in the medical insurance ranks in succession, such as to the lung cancer patient, the relevant molecule target can already be realized partly or the whole to the treatment medicine The department submits an expense account, the oral target of the stomach with therapeutic intestinal cancer has already included in the national basic medicine catalogue too to the chemotherapy medicine, have lightened the patient's financial burden greatly. The hertz of spit of fland of match passes the standard therapeutic medicine to express breast cancer as HER2, also possess the medicine economics advantage, can include of our country medical insurance in catalogue vast milk undoubtedly? Qi Does the cheek knock mother R bamboo mat?

|